The difference is that existing drugs have already undergone Phase I safety trials, which takes a lot of failure risk out of the equation. A ridiculous number

The difference is that existing drugs have already undergone Phase I safety trials, which takes a lot of failure risk out of the equation. A ridiculous number of drug candidates work, but have a side effect in a small percent of the population and never make it to market.